Avidity Biosciences has patented a polynucleic acid molecule conjugate for treating facioscapulohumeral muscular dystrophy (FSHD). The molecule targets the DUX4 gene sequence and utilizes RNA interference to combat the disease. GlobalData’s report on Avidity Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Avidity Biosciences Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Avidity Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Avidity Biosciences's grant share as of February 2024 was 22%. Grant share is based on the ratio of number of grants to total number of patents.

Polynucleic acid conjugate for treating fshd through rna interference

Source: United States Patent and Trademark Office (USPTO). Credit: Avidity Biosciences Inc

A recently granted patent (Publication Number: US11912779B2) discloses a polynucleic acid molecule conjugate designed to target the DUX4 gene. The conjugate consists of an anti-transferrin receptor antibody or its antigen binding fragment linked to a polynucleic acid molecule with specific nucleic acid sequences and modifications. The polynucleic acid molecule is engineered to mediate RNA interference against the DUX4 gene, offering a potential therapeutic approach for conditions associated with DUX4 expression.

The patent details various aspects of the polynucleic acid molecule conjugate, including the length of the molecule, specific nucleic acid sequences, modifications such as 2'-F modified nucleotides, and the composition of sense and antisense strands. Additionally, the patent describes the use of different types of antibodies or antigen binding fragments, as well as the inclusion of linkers to connect the antibody to the polynucleic acid molecule. The patent also covers the ratio between the polynucleic acid molecule and the antibody, providing a comprehensive overview of the design and potential applications of this novel conjugate for targeted gene therapy.

To know more about GlobalData’s detailed insights on Avidity Biosciences, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies